What Is It about? {#sec1_1}
=================

-   Bronchial thermoplasty is a minimally invasive treatment for asthma consisting of the thermal ablation of the bronchial smooth muscle by radiofrequency. In the present study, we describe the real-life experience with this therapy in a single center in Spain. On average, patients\' symptoms improved remarkably, the number of exacerbations was reduced by 75%, and the number of admission to the hospital was reduced by 33% in 1 year. The treatment allowed an average reduction in oral corticosteroids of 4 mg/day, which may be clinically relevant, although it was statistically nonsignificant. The most important side effect was severe exacerbations of asthma immediately after the procedure that occurred in 11% of the treatments.

Introduction {#sec1_2}
============

Asthma prevalence in Spain varies between 3 and 10% depending on the epidemiological criteria used \[[@B1]\]. In most patients, the disease is well controlled with inhaled therapy; however, in 5--10% of the asthmatic population, it is refractory to current treatment \[[@B2], [@B3]\]. Asthma patients who are refractory to treatment suffer a significant morbidity and disability despite using multiple drugs \[[@B4]\] and represent a substantial burden for health care services \[[@B5], [@B6]\].

The American Thoracic Society and European Respiratory Society define severe asthma as "asthma that requires treatment with high dose of inhaled corticosteroids (ICS) (i.e. \> 800 µg budesonide or equivalent) plus a second drug (and/or systemic CS) to prevent it from becoming uncontrolled or which remains uncontrolled despite this therapy in patients with a correct diagnosis of asthma and their comorbidities identified and treated" \[[@B7]\]. In these patients, phenotype-oriented treatments to modulate Th~2~ inflammatory response are ef fective in controlling symptoms and exacerbations; however, not all patients eligible for these therapies will achieve the desired control \[[@B3], [@B8], [@B9], [@B10]\]. Bronchial thermoplasty (BT) has proven an effective therapeutic option for patients with a nonallergic, noneosinophilic (non-Th~2~) type inflammation asthma phenotype \[[@B9], [@B10], [@B11]\]. Furthermore, BT has shown similar efficacy in patients with other asthma phenotypes and airway smooth muscle hypertrophy \[[@B9], [@B10]\]. For non-Th~2~ severe asthma, BT can be a first option for patients with persistent symptoms after failure of triple therapy with high-dose ICS plus long-acting beta-2 agonists (LABA) and tiotropium, before the use of oral corticosteroids (OCS). BT can also be considered an alternative therapy for patients with allergic or eosinophilic asthma who had an inadequate response to initial biologic therapy \[[@B9], [@B10]\].

BT is a minimally invasive procedure consisting of the application of thermal energy into the airways with the purpose of ablating the distinctive hypertrophic smooth muscle in severe asthma patients \[[@B12]\]. It was approved for use in moderate-severe asthma in Spain in 2010. Thermal energy is applied through the Alair® system (Boston Scientific, Natick, MA, USA) \[[@B12]\]. The catheter is introduced through the working channel of a flexible bronchoscope. The distal tip contains an extendable, 4-electrode basket that is deployed in accessible airways \[[@B12]\].

The objectives of the present study are to analyze the effectiveness and safety of BT under conditions of actual clinical practice, comparing the baseline situation of the patients submitted to this intervention in our center between June 2013 and September 2015 with the situation 1 year after the procedure; analyzing asthma control, reduction of treatment with ICS and OCS, number of severe exacerbations and hospital admissions, changes in lung function, and complications.

Methods {#sec1_3}
=======

This is a post-authorization cohort study. Inclusion criteria were a confirmed diagnosis of severe asthma \[[@B7]\], a history of 2 or more exacerbations requiring emergency assistance or hospital admission in the previous year, and poor symptomatic control defined as an Asthma Control Test (ACT) score of less than 20 points. Patients with nasal polyposis, allergic sinusitis, or gastroesophageal reflux were not considered candidates for BT if these conditions were not receiving adequate treatment. Patients who had vocal cord dysfunction, tracheal stenosis, or diffuse bronchiectasis on CT scan were excluded. Likewise, patients who had required admission to the intensive care unit in the previous year, were pregnant, had a peacemaker, or could not tolerate the bronchoscopy procedure were considered as unqualified for BT. Compliance with the long-term controller medication was verified by a questionnaire \[[@B13]\]. Candidates for available biological therapies according to ours or the referral center protocol were first offered this treatment. Patients who were receiving these therapies without achieving the desired control and were considered candidates for BT were also included.

From June 2013 to September 2015, we enrolled 23 patients referred to our center for BT and with a total follow-up of at least 1 year. The study was approved by the research ethics committee of our hospital and all subjects gave their written informed consent to participate.

Patients were scheduled for 3 procedures performed at least 3 weeks apart. The treat ment was administered by a team of skilled bronchoscopists licensed by the training program of the manufacturer (which includes theoretical training, visits to centers with experience, and 10 sessions of the technique supervised by experts). BT was performed with the Alair® system (Boston Scientific, Natick, MA, USA) as described in the literature \[[@B14]\]. The procedures were done under general anesthesia with the patient intubated. Three days prior to each session, the patients received 50 mg of oral prednisone and 30--90 min before each session 5 mg of nebulized salbutamol. They all remained hospitalized overnight. In case the patient had suffered a recent moderate or severe exacerbation, the procedure was postponed for 6 weeks after its resolution. The protocol consisted of a complete initial evaluation, at which it was decided whether the patients were eligible for BT, and 3 additional visits, about 2 weeks before each session, to confirm clinical stability and to schedule the procedure. One, two and seven days after every discharge, the participants were contacted by telephone. The routine management of the patients after the procedure was carried out by their referring physicians; however, patients and physicians were contacted by phone at 2, 6, and 12 months to inquire about asthma symptoms, exacerbations, medication, adverse effects and perform the ACT. Post-bronchodilator spirometry (patients\' treatment was not stopped for the test) was done at the initial evaluation and 1 year after the last BT session. Both tests were performed in a stable period defined as 6 weeks after the resolution of the last asthma exacerbation.

Exacerbations requiring an increase \> 3 days of at least 5 mg of prednisone or equivalent dose of other systemic corticosteroids were recorded. The doses of ICS and OCS are the mean doses in the 6 weeks prior to the inclusion and 1 year after the procedure visits. They were converted to budesonide- and prednisone-equivalents, respectively.

Statistical Analysis {#sec2_1}
--------------------

Effectiveness was analyzed only in the patients who completed the BT procedure (i.e., completed the 3 sessions); however, all BT sessions were included in the safety analysis. The variables are described as mean and standard deviation or proportions and standard error. Comparisons were carried out using the *t* test for paired samples or the Wilcoxon rank test if normal distribution could not be assumed. Correlations were sought by the Spearman rho coefficient. A probability of the null hypothesis (no differences between before and after) \< 0.05 was considered significant. Three points were considered as the clinically relevant difference in ACT \[[@B15]\].

Results {#sec1_4}
=======

Of the 23 patients initially included, 2 did not complete the treatment. One of them decided to drop out because she had to move abroad and the other one because she had a severe exacerbation after the first session that needed noninvasive ventilation. The remaining 21 patients (Table [1](#T1){ref-type="table"}) were predominantly female (15 out of 21, 71.4%) of middle age, 51 (8) years, ranging from 25 to 68 years old. One patient was an active smoker (4.7%) and 6 were ex-smokers for more than 1 year (28.6%). Before BT, all the participants were on LABA and ICS. The average baseline dose of ICS was 1,621 (1,015) μg of budesonide-equivalent. Nineteen (83%) were on tiotropium, 16 (76%) were using montelukast, 14 (66%) were receiving OCS as part of their regular treatment with an average dose of 15 (13) mg of prednisone-equivalent, 7 (33%) were taking theophyllines, 4 (19%) received nebulizations of 5 mg of salbutamol and ipratropium bromide 500 mg 3 times a day as additional control treatment, and 3 (14%) were on omalizumab 300 mg every 15 days (2 additional patients had been withdrawn from this medication because of inefficacy before referring them to BT). In 2 patients, FEV~1~ was \< 65%, in one of them it was 36%. The mean number of activations per patient was 147 (16), 42 (4) in the lower right lobe, 35 (3) in the lower left lobe, and 67 (5) in the upper lobes. We found a Spearman correlation of 0.255 and 0.229 (*p* = 0.200 and 0.239) between the total number of activations and the absolute reduction in severe exacerbations or hospitalizations, respectively.

ACT improved by 7.1 (3.7) points (*p* = 0.018) (Fig. [1](#F1){ref-type="fig"}). None of the patients had a worse ACT at 1 year and in 16 individuals (76%), the gain exceeded the clinically relevant difference of 3 points. The number of severe exacerbations was also reduced by 75% (9%) (Fig. [2](#F2){ref-type="fig"}), with a mean reduction of 3.5 (4.0) per patient-year (*p* \< 0.001). Only in 3 patients severe exacerbations increased or remained the same as in the previous year (Fig. [2](#F2){ref-type="fig"}). A reduction of 38% (35%) in the number of admissions was observed as well (Fig. [3](#F3){ref-type="fig"}) with a mean reduction of 0.3 (0.6) per patient-year (*p* = 0.03). In 7 patients the number of admissions was reduced and 1 patient had 1 admission more after BT than in the year before the treatment. In the other patients (most of them with no admissions in the previous year) there were no changes.

At 1 year, 4 (28%) of the 14 patients on OCS at baseline were not using OCS, 4 (28%) had reduced the dose (by 80, 50, 33, and 20%, respectively), 3 (21%) were on the same dose, and 3 (21%) needed a higher dose (Table [2](#T2){ref-type="table"}). One additional patient, who was not taking OCS at visit 1, was using them after the treatment (average dose 1.6 mg). The mean reduction of OCS was of 4 (11) mg (*p* = 0.094). Treatment with theophyllines was discontinued in 4 patients, and the dose was reduced in 2. There were no changes in patients receiving leukotriene antagonists or omalizumab. Two of the 4 patients who were being treated with nebulized medication had suspended it. There were no changes in the lung function with a mean difference of −0.5 (2.77%) of predicted FEV~1~.

The most frequent complications were severe asthma exacerbations in the days following the bronchoscopy (Table [3](#T3){ref-type="table"}). One case required noninvasive mechanical ventilation. We had a case of major hemoptysis 23 days after the last session in a patient treated with clopidogrel and aspirin due to a transient ischemic attack (which was discontinued for BT and restarted after the procedure). She had nonsymptomatic isolated bronchiectasis on chest CT scan.

Discussion {#sec1_5}
==========

The present article describes our clinical practice and experience with BT. We found that BT improved symptoms and reduced severe exacerbations in a magnitude similar to the randomized controlled trials "Asthma Intervention Research Trial" (AIR) AIR-1 and AIR-2 \[[@B11], [@B16]\] -- which were the basis for the Food and Drug Administration approval --, other observational studies in different countries \[[@B17], [@B18], [@B19]\], and a recently published cohort of 190 patients (PAS-2) \[[@B20]\].

Our patients have a comparable lung function to that of the AIR-2 and PAS-2 partici pants -- allowing for small divergences as percent predicted values due to the use of different reference values \[[@B11], [@B20], [@B21]\] -- however, they were clinically more severe than the AIR-2 and PAS-2 patients \[[@B11], [@B20]\], with more severe exacerbations before BT treatment.

We observed a moderate sparing effect of BT on medication in our patients. ICS were reduced by 430 (720) μg (*p* \< 0.02) of budesonide-equivalent. Similarly to the PAS-2 study \[[@B20]\], we saw a tendency towards a reduction of the OCS (*p* = 0.094), with 8 out of the 14 patients (57%) who were using OCS at the initial visit being able to stop or reduce the dose; however, this effect was not consistent in all the participants, resulting in a modest average reduction of 4 (11) mg (*p* = 0.094); the study was not designed to look into the factors differentiating those who could and those who could not reduce OCS and the sample was small to achieve sufficient statistical power; thus, the finding can only be taken as a hypothesis-generating observation. Finally, there was also a reduction in the use of theophyllines and nebulizer bronchodilators.

Regarding omalizumab, in the few patients in whom its use was combined with BT, it appeared to improve asthma control, proposing again the hypothesis that BT may be an add-on option for patients who do not respond satisfactorily to biological treatments.

The proportion of adverse effects in our study was slightly lower than in the AIR-2 and PAS-2 studies (Table [3](#T3){ref-type="table"}). As we did not see respiratory tract infections, the risk of exacerbations was slightly lower, and the incidence of atelectasis and hemoptysis was similar \[[@B11], [@B20]\]. Our patients occasionally reported mild chest pain for a few days after the procedure, with no radiological or long-lasting clinical consequences, which was managed with nonsteroidal anti-inflammatory drugs. This side effect was neither described in AIR-2 \[[@B11]\] nor in PAS-2 \[[@B20]\].

The mechanisms that underlie a better asthma control after BT remain unclear. Several studies have shown that there is a significant reduction of the smooth muscle \[[@B22], [@B23], [@B24], [@B25]\]; this is still considered the main mechanism of action, but the smooth muscle also participates in the immune regulation of the bronchial wall \[[@B26], [@B27]\], and some studies suggest that BT can modify the bronchial and systemic inflammatory profile \[[@B28], [@B29]\]. Moreover, some work suggests that BT can decrease submucosal nerve endings, which are known to be involved in the regulation of smooth muscle tone and bronchial hyperreactivity \[[@B24]\]. Several studies are currently underway to evaluate the molecular, cellular, and pathological changes that may occur after treatment with BT \[[@B30], [@B31], [@B32]\].

The limitations of this study are the relatively small number of patients included, which does not allow establishing relationships to define predictors of response to BT. Several studies are now in course aimed to identify such factors \[[@B33], [@B34]\]. Our study is an observational one, which may have led to certain bias when interpreting effectiveness and safety; nonetheless, as we have already mentioned, the results are very similar to other observational studies \[[@B17], [@B18], [@B19], [@B20]\] and to the randomized controlled trials AIR-1 and AIR-2 \[[@B11], [@B16]\], the latter blinded and placebo-controlled, thus it can be considered as an open-label confirmatory study in a different setting and in actual clinical practice conditions. We did not see im provement in FEV~1~; however, the effects on lung function are very difficult to measure in a study like the present one, since the participants had severe asthma and we considered it not appropriate to withdraw the medication. Baseline lung function, therefore, was measured while taking their regular medication. We calculated the average dose of medication the patients were using during the 6 weeks before the first and last visits, but not the total dose used in the previous year. We feel that 6 weeks is a representative period of the medication need of the patients, particularly because the enrollment visit was not determined by the investigators and the 1-year visit was predetermined at the enrollment of the patients and did not depend on their control status. Moreover, the medication-sparing effect in a longer period of time, if any, would have been even higher since there was an important reduction (by 75%) in moderate-severe asthma exacerbations and the control of the patients, as measured by ACT, had markedly improved after BT.

Conclusions {#sec1_6}
===========

In patients with very severe asthma, BT is as effective in clinical practice as in clinical trials, which generally included less severe patients. In our practice it had some medication-sparing effect that was very relevant (withdraw of OCS) for a selected number of patients. It is a safe technique; however, based on our experience with 1 case, we recommend special caution in patients with bronchial dilations, even if asymptomatic.
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###### 

Baseline characteristics of the population

  Variable                                    Mean (SD)
  ------------------------------------------- ------------
  FEV!, % predicted                           79 (17)
  Age, years                                  51 (8)
  ACT score                                   7.2 (1.5)
  Severe exacerbations in the previous year   4.5 (4.1)
  Hospital admissions in the previous year    0.85 (1.3)

ACT, Asthma Control Test.

###### 

Use of corticosteroids at baseline and 1 year after BT

                              Mean (SD)       
  --------------------------- --------------- -------------
  Budesonide-equivalent, pg   1,641 (1,014)   1,191 (701)
  Prednisone-equivalent, mg   15 (13)         11 (10)

BT, bronchial thermoplasty; SD, standard deviation.

###### 

Adverse effects of bronchial thermoplasty (*n* = 65 sessions)

  Complication                        Absolute (relative) frequency
  ----------------------------------- -------------------------------
  Asthma exacerbation                 7 (10.6%)
   Delayed discharge \<7 days         6 (9.1%)
   Delayed discharge \>7days + NIMV   1 (1.5%)
  Atelectasis                         2 (3.0%)
  Chest pain                          6 (9.2%)
  Severe hemoptysis (after 23 days)   1 (1.5%)

NIMV, noninvasive mechanical ventilation.
